4.3 Review

A safety review of drugs used for the treatment of retinopathy of prematurity

Journal

EXPERT OPINION ON DRUG SAFETY
Volume 19, Issue 11, Pages 1409-1418

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1080/14740338.2020.1826927

Keywords

Antioxidants; anti-VEGF; hyperoxia; hypoxia; IGF-1; NSAIDs; propranolol; steroids; VEGF

Funding

  1. University of Pisa

Ask authors/readers for more resources

Introduction Retinopathy of Prematurity (ROP) is a sight-threatening disease representing one of the main disabling diseases affecting premature newborns. Presently, ROP is treated by surgical interventions and drug therapies are limited to the off-label use of a little amount of molecules approved for other pathologies. Areas covered Many drugs that may potentially be used in treating ROP are recently proposed, in many cases after the demonstration of their effectiveness in preclinical studies. In this review, the authors discuss safety and effectiveness of the main proposed approaches in the pharmacologic treatment of the disease, including approaches based on oxygen therapy and nutritional interventions. Expert opinion Surgical approaches to ROP are not without side effects. However, most of the proposed pharmacologic interventions can also raise specific concerns. In particular, these approaches follow a curative paradigm and are proposed in patients once the disease has progressed, with an effectiveness that is often smaller than expected. A goal in the treatment of ROP would be moving the paradigm toward a preventive approach that could be potentially effective in treating extremely low birth weight preterm infants before ROP becomes manifest.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available